GlySure Ltd.
This article was originally published in Start Up
Executive Summary
Despite mounting evidence that controlling blood sugar levels in critical care patients reduces complications and shortens the length of ICU stay, clinicians have found total glucose control hard to achieve because of the frequent testing required to achieve tight management. GlySure Ltd. is developing a continuous intravascular glucose monitoring system based on optical fluorescence. The start-up says that its sensor, inserted into the patient through central venous or arterial lines, can be used to monitor glucose and other parameters continuously for long periods of time without clotting or other adverse effects.
You may also be interested in...
Start-Up Previews
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.